Mural Health is a clinical trials technology company that is dedicated to making it easy to be a participant in clinical trials. Mural Health’s technology platform, Mural Link, is a patient-first technology that is primarily designed to benefit the study participant but also improves site operations and drives critical strategic value to study sponsors. Join our email list here: https://www.muralhealth.com/newsletter/signup
External link for Mural Health
1189 Lancaster Ave
Berwyn, Pennsylvania 19312, US
Mural Health will be at OCT West Coast February 11-12. Will you!? Stop by booth 86 or pre book 15 minutes with our very own Allie Grodin and Joshua McVoy at the link below 👇 https://hubs.ly/Q034nc250
This content isn’t available here
Access this content and more in the LinkedIn app
“Despite all the whizbang technology, improved trial design, and new regulations, there's one obstacle that still plagues trial participants, especially those in underserved communities. Taxes.” Many thanks to Dan Schell from Clinical Leader for shedding light on the tax burden that clinical trial participants often face, and for mentioning Mural Health's leadership in making clinical trials more accessible through the Harley Jacobsen Act. Read the article from Clinical Leader here: https://hubs.ly/Q0348jzc0 Society for Clinical Research Sites (SCRS) #clinicaltrials #muralhealth
Are you keeping track of the latest developments on the 21st Century Cures Initiative? For anyone working in clinical research – especially those working to break down barriers to participation – we encourage you to follow it. When we first saw the news that Congress was developing Cures 2.1 – and in particular its mention of expanding access to telehealth – it immediately brought to mind Marcelo Ramalho-Ortigao - a scientist, professor, and pediatric patient advocate who shared his story with us through The Portrait Project (You can read his story in the comments). Marcelo lost his 10-year-old daughter, Juliana, to DIPG, an aggressive pediatric brain tumor. Driven by his loss, he now works to advance policies for pediatric diseases – diseases that are often called “rare,” but in actuality are neglected. In 2020, Marcelo completed a white paper on the 21st Century Cures Act, where he advocates for integrating telehealth into clinical trials—an approach that removes geographic and financial barriers, enhances diversity, and supports participation for children with severe conditions. We encourage you to read his white paper here: https://hubs.ly/Q033RBfs0 #ClinicalTrials #PatientStories #Caregivers
We're gearing up for #SCOPESummit 2025 in Orlando next week! Swing by booth #232 to chat with us about how we make it easier to participate in clinical trials. We'd love to hear your challenges and see how we can help. What’s on your radar for the summit? What are you hoping to learn? Let’s connect and share ideas. Book a 15-minute meeting with our team using the link below—we’d love to chat! https://hubs.ly/Q033CQKY0
We're excited to start sharing our Monthly Newsletter here on LinkedIn, where we spotlight the issues and initiatives we’re invested in -- the ones we know will move the needle for #participants. Click below to subscribe and read our January edition. Here's what you can expect each month: ⚖️ Updates on our work to remove barriers to clinical trial participation, including tech innovation through our participant management platform, Mural Link, and our legislative work through The Harley Jacobsen Clinical Trial Act. 🌐 Industry news, insights & events (+ where to find us next) 💡Thought-provoking topics from our founder and CEO, Samuel Whitaker 🗣️The latest stories from The Portrait Project (https://hubs.ly/Q033zmQ30) #Clinicaltrials #Newsletter #MuralHealth
We're excited for the #SCOPEsummit 2025 in a few weeks! Will we see you there? Stop by booth 232 or pre-book 15 minutes with our team at the link below 👇 https://lnkd.in/eDPaq8cX
This content isn’t available here
Access this content and more in the LinkedIn app
Thank you for the feature, Micah Lieberman! Mural Health founder & CEO, Samuel Whitaker, joined Micah to preview #SCOPEsummit and our finalist nomination for the 2025 Participant Engagement Award. If you will be attending SCOPE, stop by booth 232 to learn more about how Mural makes it easier to be a participant in clinical trials. #clinicaltrials #clinicalops #digitalhealth
Executive Director (CHI and SCOPE) & Co-Founder, VP, Community and Business Development (ClinEco)
It is a well-known problem that clinical trials do not test therapies on patient populations that reflect the diversity of the people that those therapies are meant to serve. For this reason, increasing #diversity in #clinicaltrials has been recognized as a priority, advanced by federal agency offices such as the FDA and the NIH. A key reason for the lack of trial diversity is that payments made to trial participants, unless labeled as a reimbursement, are considered income and must be reported to the IRS. This is why Mural Health initiated the Harley Jacobsen Act, seeking to exclude all payments (regardless of their labeling) to all participants (including caregivers) in all clinical trials (vs. only some trials for some therapeutic areas) from being treated as taxable income. Samuel Whitaker, Founder and CEO of Mural Health, talks about removing tax barriers from clinical trial participation and the Harley Jacobsen Act. They are a finalist at #SCOPEsummit's 2025 Participant Engagement Award and we are grateful for the legislative work they are doing. https://lnkd.in/dMdSM-Y MORE BEHIND THE STORY: The Harley Jacobsen Act is named after the late Harley Jacobsen, a dear friend of Sam Whitaker, Mural Health’s founder and CEO. Harley was diagnosed with ALS in his mid-30s. Following his diagnosis, Harley enrolled in a clinical trial. Over the course of the next year, Harley and his wife, Maureen, traveled to Boston from Pennsylvania 14 times. They incurred ~$19,000 worth of trial related expenses in the form of gas, tolls, lodging, and more. Only $1200 of Harley and Maureen’s expenses were covered by the trial sponsor, but because these funds were paid out as a stipend, the IRS considered the $1,200 as income, and the Jacobsen family had to pay taxes on them, despite being at a net loss of ~$17,000. To participate, Harley and Maureen had to lean on their community to help them pay for their expenses. The trial did not help Harley, and he passed away, leaving behind Maureen and their two daughters. Several years after his passing, the family learned that Harley was part of the placebo arm, and never received the experimental drug. The Jacobsen family’s story is one of many stories of families who incur significant financial losses to participate in a trial that is their only hope, but are still taxed for the payments they receive to mitigate those losses. RELEVANT LINKS: - Mural Health’s webpage sharing more on the Harley Jacobsen Act and tracking its progression https://lnkd.in/g-fdfiTR - The Harley Jacobsen Act: https://lnkd.in/gGAAqh28 Oshrat Goldberg, Emma Eikermann, Nicole Nackley Kerr, Bridget Kotelly, Clinical Research News, Andy Studna, Moe Alsumidaie, David Sall, Kelly McKee, Stacy Hurt 🌻, Jen Horonjeff, Michelle Everill, Gretchen Goller, Otis Johnson, PhD, MPA, Kim Ribeiro, Tricia Barrett
Mural Health reposted this
In case you missed it, a white paper was announced outlines next steps for the Cures 2.1 and the 21st Century Cures initiatives. This work is on the heels of hundreds of recommendations from industry leaders — including Mural Health— to further innovation and open access to quality health care. Take a look at page 7. The white paper addresses access to clinical trials, specifically calling out the financial barriers to entry and the significant costs associated with participation.
We are honored that Mural Health has been named a finalist for the 2025 SCOPE Summit Participant Engagement Award (PEA), for our work to make clinical trials more accessible and diverse through the Harley Jacobsen Clinical Trial Act. In order to promote a more diverse trial population and drug development process, we need to make it possible for all Americans to participate. The Harley Jacobsen Act is a key step in that mission. Currently, the 110M Americans on a social welfare program are prevented from participating in trials, because those payments are very often mislabeled as taxable income, which threatens to disqualify low-income Americans from receiving government benefits like Medicaid and SNAP. The Harley Jacobsen Act seeks to change this by excluding all payments - to all participants - in all clinical trials from being treated as taxable income. We'll be sharing more about our finalist nomination in the weeks leading up to the 2025 SCOPE Summit (February 3-6 in Orlando), so stay tuned! In the meantime, learn more about the awards here: https://lnkd.in/gs4jAhBq #SCOPEsummit #clinicaltrials #clinicalops #digitalhealth
Our participant survey closes January 31st! If you haven’t yet taken it or shared it, we would be so appreciative if you would. We created this survey to better understand the participant experience in clinical trials — specifically the costs associated with participating — so that we can better advocate for fair reimbursements. This survey is intended for patients (or caretakers on their behalf) who have participated in or are currently in at least one clinical trial. All responses will remain anonymous. Take or share the survey using this link: https://hubs.ly/Q031Yh2w0 Thank you in advance for supporting our mission of making it easier to participate in clinical trials 😊 #clinicaltrials #clinicalresearch #participantpayments